Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 104
of 6Next
1:

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.

Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS.

J Cardiovasc Magn Reson. 2008 Jan 22;10(1):5.

PMID: 18272009 [PubMed - indexed for MEDLINE]

2:

[Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer]

Menke-van der Houven van Oordt CW, Fliervoet HJ, Mandigers CM, van Spronsen DJ.

Ned Tijdschr Geneeskd. 2008 Jan 19;152(3):158-63. Dutch.

PMID: 18271465 [PubMed - indexed for MEDLINE]

3:

Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.

Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke DA, Gerstenblith G, Marbán E, Tomaselli GF, Lima JA.

J Am Coll Cardiol. 2008 Jun 24;51(25):2414-21.

PMID: 18565399 [PubMed - indexed for MEDLINE]

4:

Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.

Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG.

Kidney Int. 2006 May;69(10):1839-45.

PMID: 16508657 [PubMed - indexed for MEDLINE]

5:

Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer.

Tham YL, Verani MS, Chang J.

Breast Cancer Res Treat. 2002 Jul;74(2):131-4.

PMID: 12186373 [PubMed - indexed for MEDLINE]

6:

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Telli ML, Hunt SA, Carlson RW, Guardino AE.

J Clin Oncol. 2007 Aug 10;25(23):3525-33. Review.

PMID: 17687157 [PubMed - indexed for MEDLINE]

7:

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J.

J Clin Oncol. 2005 Nov 1;23(31):7811-9.

PMID: 16258083 [PubMed - indexed for MEDLINE]

8:

Trastuzumab-induced cardiomyopathy.

Guglin M, Cutro R, Mishkin JD.

J Card Fail. 2008 Jun;14(5):437-44. Review.

PMID: 18514938 [PubMed - indexed for MEDLINE]

9:

Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.

Hsiang DJ, Yamamoto M, Mehta RS, Su MY, Baick CH, Lane KT, Butler JA.

Arch Surg. 2007 Sep;142(9):855-61; discussion 860-1.

PMID: 17875840 [PubMed - indexed for MEDLINE]

10:

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID: 12885806 [PubMed - indexed for MEDLINE]

11:

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WT, Sluiter WJ, van Veldhuisen DJ, Suter TM, Sleijfer DT, Perik PJ.

Eur J Cancer. 2007 Sep;43(14):2046-51. Epub 2007 Aug 24.

PMID: 17719768 [PubMed - indexed for MEDLINE]

12:

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.

Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF; Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group.

Br J Cancer. 2006 Apr 10;94(7):1016-20.

PMID: 16570045 [PubMed - indexed for MEDLINE]

13:

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG.

J Clin Oncol. 2006 May 20;24(15):2276-82.

PMID: 16710024 [PubMed - indexed for MEDLINE]

14:

Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).

Fuchs IB, Landt S, Bueler H, Kuehl U, Coupland S, Kleine-Tebbe A, Lichtenegger W, Schaller G.

Breast Cancer Res Treat. 2003 Nov;82(1):23-8.

PMID: 14672400 [PubMed - indexed for MEDLINE]

15:

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ.

J Clin Oncol. 2005 Nov 1;23(31):7820-6.

PMID: 16258084 [PubMed - indexed for MEDLINE]

16:

Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.

Millar JA, Millward MJ.

Pharmacoeconomics. 2007;25(5):429-42.

PMID: 17488140 [PubMed - indexed for MEDLINE]

17:

[Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy]

Dumont CA, Monserrat L, Soler R, Rodríguez E, Fernández X, Peteiro J, Bouzas B, Piñón P, Castro-Beiras A.

Rev Esp Cardiol. 2007 Jan;60(1):15-23. Spanish.

PMID: 17288951 [PubMed - indexed for MEDLINE]

18:

Primary myocardial dysfunction in autosomal dominant EDMD. A tissue doppler and cardiovascular magnetic resonance study.

Smith GC, Kinali M, Prasad SK, Bonne G, Muntoni F, Pennell DJ, Nihoyannopoulos P.

J Cardiovasc Magn Reson. 2006;8(5):723-30.

PMID: 16891232 [PubMed - indexed for MEDLINE]

19:

Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

Ewer MS, Gibbs HR, Swafford J, Benjamin RS.

Semin Oncol. 1999 Aug;26(4 Suppl 12):96-101.

PMID: 10482200 [PubMed - indexed for MEDLINE]

20:

[Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography]

Hattori K, Nishi Y, Nakamura S, Misao H, Kikuchi M, Sasaki R, Takeda K.

Rinsho Byori. 2007 Feb;55(2):120-5. Japanese.

PMID: 17390714 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 104
of 6Next